Hypercalcemia After Paraffin Oil Injection

Hypercalcemia Clinical Trial

Official title: Hypercalcemia After Paraffin Oil Injection: Aetiology, Pathogenesis and Possible Treatment Options

Status Recruiting

Clinical Trial Summary

Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case reports have suggested that intramuscular injection of paraffin oil induces foreign body reaction and granuloma formation and subsequently hypercalcemia. Our hypothesis is that increased generation of activated vitamin D (1,25(OH)2D3) in the marcrophages may be responsible for the persistent hypercalcemia. Now trhe investigators want to include a large group of men who injected 100-10.000 ml paraffin oil to identify risk factors for developing hypercalcemia and try to understand the pathogenesis of the disease. Additionally, granuloma tissue from selected patients will be cultured ex vivo to investigate whether they produce 1,25(OH)2D3 or PTHrP and to test which drugs can most effectively be used to lower calcium levels in these men. Subsequently, we will try to stratify the men according to the severity of the changes in calcium homeostasis as we suggest that this stratification will be the basis for future intervention trials

Clinical Trial Description

Today, there is an increased use of non-medical, invasive cosmetic treatments globally without sufficient awareness of possible health risks. A particular problem is young men injecting large amounts of paraffin oil into skeletal muscles especially on upper arms and chest to increase the visible size of the muscles. Several case reports have suggested that intramuscular injection of paraffin oil induces foreign body reaction and granuloma formation. The formation of granuloma probably precedes the marked hypercalcemia that often develops and appears to be difficult to treat. The largest study to date included 14 men and showed that practically all men developed serious hypercalcemia, but the etiology was unclear. Foreign body granulomas are like other granulomatous diseases such as Tuberculosis or sarcoidosis rich in macrophages, (ref) and it has been proposed that increased generation of activated vitamin D (1,25(OH)2D3) in the marcrophages may be responsible for the persistent hypercalcemia.

Calcium homeostasis is tightly regulated primarily by vitamin D, Parathyroid hormone (PTH) and Fibroblast growth factor 23 (FGF23) that rapidly modifies intestinal absorption, renal excretion and calcium mobilization from the skeletal compartment in response to immediate changes in serum calcium (ref). Vitamin D (cholecalciferol) is normally formed by UV-B radiation of the skin and requires two enzymatic reactions before it can bind and activate the vitamin D receptor (VDR). Conversion of cholecalciferol to 25-hydroxydvitamin (25OHD) is the first activation step; it is un-regulated and generally exerted by the hepatic CYP2R1. 25OHD is not biologically active and must undergo 1-alpha hydroxylation by renal CYP27B1 to form the active metabolite 1,25(OH)2D3. The main actions of 1,25(OH)2D3 is to promote calcium and phosphate absorption and decrease calcium excretion until inactivated by CYP24A1. 1,25(OH)2D3 is also a powerful inhibitor of PTH and inducer of FGF23, which ensures an important feedback-loop to maintain an adequate vitamin D status (ref). PTH which is a potent inducer of CYP27B1, mobilizes calcium and phosphate from the skeleton and increases phosphate excretion. In contrast, FGF23 that inhibits CYP27B1, induces the in-activating CYP24A1 and promotes phosphate excretion. Almost all organs has the ability to activate, respond to, and inactivate vitamin D because CYP27B1, VDR and CYP24A1 are expressed also in most non-renal tissues. However, regulation of CYP27B1 and CYP24A1 is strikingly different in these organs where high intracellular levels of 1,25(OH)2D3 activates VDR that induces transcription of CYP24A1 and thereby increases in-activation to restore normal intracellular levels of all vitamin D metabolites. This autoregulatory control of vitamin D metabolites secures under normal circumstances that high concentrations of 1,25(OH)2D3 are not released into circulation. Regulation of vitamin D homeostasis is different in the macrophages present in granulomas because they retain a splice variant of CYP24A1 that is not upregulated in response to high 1,25(OH)2D3 levels, which in part explains the increased release of 1,25(OH)2D3 in granulomatosis disease. Another important issue is aberrant regulation of CYP27B1 in macrophages, which is induced by inflammatory signals such as interleukin-2 and TNF-alpha rather than PTH. Previous case reports have detected CYP27B1 expression in granuloma tissue by immunohistochemistry. However, these findings have to our knowledge never been corroborated by a more comprehensive analysis of enzyme activity and a recent study questioned the etiology because most men with granulomas had normal levels of 1,25(OH)2D3 in serum (ref).

In the present study the investigators want to include a large group of men who injected 100-10.000 ml paraffin oil to identify risk factors for developing hypercalcemia and try to understand the pathogenesis of the disease. Additionally, granuloma tissue from selected patients will be cultured ex vivo to investigate whether they produce 1,25(OH)2D3 or PTHrP and to test which drugs can most effectively be used to lower calcium levels in these men. Subsequently, elucidate whether it is possible to stratify the men according to the severity of the changes in calcium homeostasis as such a stratification may be required prior to and form the basis for future intervention trials ;

Related Conditions & MeSH terms

• Granuloma
• Hypercalcemia

• NCT number: NCT04292288
• Study type: Observational
• Source: Rigshospitalet, Denmark
• Contact: Martin Blomberg Jensen
• Phone: +4535453545
• Email: blombergjensen@gmail.com
• Status: Recruiting
• Start date: April 1, 2019
• Completion date: January 1, 2028